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Abstract. 
 
Glycogen synthase kinase 3 (GSK-3) is a 
constitutively active kinase that negatively regulates its 
substrates, one of which is 
 
b
 
-catenin, a downstream ef-
fector of the Wnt signaling pathway that is required for 
dorsal–ventral axis speciﬁcation in the 
 
Xenopus
 
 em-
bryo. GSK-3 activity is regulated through the opposing 
activities of multiple proteins. Axin, GSK-3, and 
 
b
 
-cate-
nin form a complex that promotes the GSK-3–medi-
ated phosphorylation and subsequent degradation of
 
b
 
-catenin. Adenomatous polyposis coli (APC) joins the 
complex and downregulates 
 
b
 
-catenin in mammalian 
cells, but its role in 
 
Xenopus
 
 is less clear. In contrast, 
GBP, which is required for axis formation in 
 
Xenopus
 
, 
binds and inhibits GSK-3. We show here that GSK-3 
binding protein (GBP) inhibits GSK-3, in part, by
preventing Axin from binding GSK-3. Similarly, we 
present evidence that a dominant-negative GSK-3 mu-
tant, which causes the same effects as GBP, keeps en-
dogenous GSK-3 from binding to Axin. We show that 
GBP also functions by preventing the GSK-3–mediated 
phosphorylation of a protein substrate without elimi-
nating its catalytic activity. Finally, we show that the 
previously demonstrated axis-inducing property of 
overexpressed APC is attributable to its ability to stabi-
lize cytoplasmic 
 
b
 
-catenin levels, demonstrating that 
APC is impinging upon the canonical Wnt pathway in 
this model system. These results contribute to our 
growing understanding of how GSK-3 regulation in
the early embryo leads to regional differences in
 
b
 
-catenin levels and establishment of the dorsal axis.
Key words: Wnt pathway • dorsal/ventral • 
 
b
 
-catenin
 
Introduction
 
The Wnt family of secreted glycoproteins are important
mediators of a variety of developmental processes across
animal phyla, and also have roles in cell proliferation and
oncogenesis. From genetic data obtained in 
 
Drosophila
 
and biochemical and cell biological data in 
 
Xenopus
 
 and
mammalian cell culture, a great deal has been learned
about this developmentally crucial pathway (for reviews
see Dale, 1998; Wodarz and Nusse, 1998). Wnts signal
through receptors of the frizzled class (Bhanot et al., 1996;
Yang-Snyder et al., 1996; He et al., 1997), leading to the
hyperphosphorylation of Dishevelled (Yanagawa et al.,
1995), a protein of unknown function. Activation of Di-
shevelled leads to the inhibition of the serine/threonine ki-
nase glycogen synthase kinase 3 (GSK-3)
 
1
 
 (Noordermeer
et al., 1994; Siegfried et al., 1994; Wagner et al., 1997),
which, in the absence of Wnt signaling, binds Axin and
phosphorylates 
 
b
 
-catenin (Yost et al., 1996; Hart et al.,
1998; Ikeda et al., 1998; Kishida et al., 1998; Nakamura et al.,
1998; Sakanaka et al., 1998), targeting it for ubiquitination
and subsequent degradation by the proteosome pathway
(Aberle et al., 1997; Orford et al., 1997). Therefore, Wnt
signaling results in the stabilization of 
 
b
 
-catenin by inhibi-
tion of GSK-3. Cytoplasmic 
 
b
 
-catenin associates with
HMG box class transcription factors of the Lef/Tcf fami-
 
lies (Behrens et al., 1996; Miller and Moon, 1996;
Molenaar et al., 1996) to activate the transcription of tar-
get genes (Brannon et al., 1997; Laurent et al., 1997;
McKendry et al., 1997).
A large body of evidence has implicated the Wnt path-
way in the establishment of the early dorsal signaling cen-
ter in 
 
Xenopus 
 
(for reviews see Harland and Gerhart,
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1997; Heasman, 1997; Moon and Kimelman, 1998). In re-
sponse to sperm entry, a microtubule array is established
that causes a rotation of a thin layer of cortical cytoplasm
towards the side opposite sperm entry (Elinson and
Rowning, 1988). Cortical rotation leads to the movement
of a transplantable dorsalizing activity from the vegetal
pole of the egg to the future dorsal side of the embryo
(Fujisue et al., 1993; Kikkawa et al., 1996; Sakai, 1996;
Rowning et al., 1997). Positive effectors of the Wnt path-
way, when overexpressed ventrally, mimic this endoge-
nous dorsalizing activity (Moon and Kimelman, 1998).
However, the role of more upstream members of the path-
way, Wnt itself and Dishevelled, is still unclear. Dominant-
negative versions of these proteins do not affect axis for-
mation (Hoppler et al., 1996; Sokol, 1996), but it may not
be possible to introduce these constructs early enough to
affect endogenous axis formation. Two recent findings
leave open the possibility that these upstream components
of the pathway may play a role. First, Dishevelled has
been shown recently to be enriched dorsally in one-cell
embryos, and ectopic GFP-tagged Dishevelled is trans-
ported along the microtubule array during cortical rota-
tion (Miller et al., 1999). Second, a maternal Wnt, Wnt-11,
has been shown recently to be asymetrically distributed at
the protein level as a result of asymmetric polyadenyla-
tion, which is dependent on cortical rotation (Schroeder
et al., 1999).
Numerous studies indicate that the dorsal determinant
functions to inhibit GSK-3 activity. A kinase dead GSK-3
acts as a dominant-negative, duplicating the axis when ex-
pressed ventrally (Dominguez et al., 1995; He et al., 1995;
Pierce and Kimelman, 1995), and a 
 
b
 
-catenin mutant that
lacks the GSK-3 phosphorylation sites necessary for its
degradation is a more potent axis inducer than the wild-
type protein (Yost et al., 1996). 
 
b
 
-Catenin is required for
axis formation (Heasman et al., 1994) and is enriched dor-
sally by the two-cell stage in a manner dependent on corti-
cal rotation (Larabell et al., 1997). The dorsal accumula-
tion of 
 
b
 
-catenin activates transcription of dorsal-specific
genes such as 
 
siamois
 
 (Brannon et al., 1997) and 
 
Xnr-3
 
(McKendry et al., 1997). Finally, the embryonic cytoplasm
containing the dorsalizing activity can cause nuclear accu-
mulation of 
 
b
 
-catenin and induce expression of 
 
siamois
 
and 
 
Xnr3
 
 (Darras et al., 1997; Marikawa et al., 1997).
With 
 
b
 
-catenin established as the direct regulator of
gene transcription downstream of Wnt signaling, and
GSK-3 established as the direct regulator of cytoplasmic
 
b
 
-catenin levels, attention has shifted to the question of
how GSK-3 itself is regulated in the early embryo. Two
novel families of GSK-3 binding proteins (GBP) have been
identified, and both clearly have been shown to regulate
GSK-3 function, although in opposite ways. The first of
these families of GSK-3 binding proteins includes 
 
Xeno-
pus
 
 GBP and the mammalian FRATs (Jonkers et al., 1997;
Yost et al., 1998). GBP is required for the formation of the
endogenous 
 
Xenopus
 
 axis, and both GBP and FRAT2
have axis-inducing activity when ectopically expressed in
 
Xenopus
 
 (Yost et al., 1998). Ectopic GBP stabilizes 
 
b
 
-cat-
enin levels in 
 
Xenopus
 
 (Yost et al., 1998), and FRAT1 ele-
vates the level of cytosolic 
 
b
 
-catenin in NIH3T3 cells
(Yuan et al., 1999). GBP inhibits the ability of GSK-3 to
phosphorylate a protein substrate, tau, in an in vivo assay,
suggesting that GBP inhibits the kinase function of GSK-3
(Yost et al., 1998). The presence of mammalian homo-
logues, and the fact that 
 
FRAT1
 
 was cloned as a cooperat-
ing oncogene which confers a selective advantage to Myc-
and Pim1-expressing tumors (Jonkers et al., 1997), suggest
that this family of GSK-3 inhibitors is important in pro-
cesses besides 
 
Xenopus
 
 axis formation. At present, GBP is
the most upstream component shown to be required for
specification of the endogenous dorsal axis, though whether
it plays a role in all Wnt-mediated signaling events is an
open question. It is possible that GBP activates a unique
maternal Wnt-related intracellular pathway, independent
of Wnt ligand.
The second of these GSK-3 binding protein families in-
cludes Axin (Zeng et al., 1997) and the related proteins
Axil (Yamamoto et al., 1998) and Conductin (Behrens et
al., 1998). Axin functions as a scaffolding protein that di-
rectly binds both GSK-3 and its substrate 
 
b
 
-catenin (Hart
et al., 1998; Ikeda et al., 1998; Kishida et al., 1998; Naka-
mura et al., 1998; Sakanaka et al., 1998) and greatly en-
hances GSK-3’s ability to phosphorylate 
 
b
 
-catenin (Hart
et al., 1998; Ikeda et al., 1998), leading to its degradation
(Aberle et al., 1997; Hart et al., 1998). 
 
Axin
 
 mutations in
the mouse embryo lead to axis duplication, and overex-
pression of Axin on the dorsal side of the 
 
Xenopus
 
 embryo
abolishes the endogenous axis (Zeng et al., 1997). In
 
Drosophila
 
, D-Axin is required for the negative regulation
of Wg signaling (Hamada et al., 1999; Willert et al., 1999),
 
d-axin
 
 mutant clones contain elevated levels of the 
 
Dro-
sophila
 
 homologue of 
 
b
 
-catenin, Arm (Hamada et al.,
1999), and D-Axin interacts with Arm and Zeste-white 3
(Willert et al., 1999). Axin is a maternal protein, present
throughout development (Zeng et al., 1997; Hamada et al.,
1999; Hedgepeth et al., 1999) and found throughout adult
mouse tissues (Zeng et al., 1997). The ubiquitous expres-
sion of Axin, and its presence in both vertebrates and in-
vertebrates, suggests that it plays a role in a broad range of
GSK-3–regulated processes.
Axin functions as part of a multiprotein complex that
also includes the APC tumor suppressor protein (for re-
views see Polakis, 1997; Bienz, 1999). APC directly binds
Axin and 
 
b
 
-catenin in a protein complex that includes
GSK-3 (Rubinfeld et al., 1996; Hart et al., 1998; Kishida et al.,
1998). Cell culture experiments have implicated APC in
the downregulation of 
 
b
 
-catenin (Munemitsu et al., 1995;
Hayashi et al., 1997; Hart et al., 1998), although studies
in 
 
Xenopus
 
 have suggested that APC has an alternative
role, activating dorsal axis formation in a pathway re-
quiring 
 
b
 
-catenin but independent of 
 
b
 
-catenin stabiliza-
tion (Vleminckx et al., 1997). Thus, a picture has begun to
emerge wherein multiple proteins with opposing effects
converge on GSK-3 to regulate its activity and, therefore,
cytoplasmic 
 
b
 
-catenin levels. The next question is how are
these various inputs on GSK-3 activity integrated to regu-
late the level of 
 
b
 
-catenin available for transcription of tar-
get genes? We sought to build on our previous work show-
ing that GBP inhibits GSK-3 by determining how this
inhibition occurs, and specifically, how GBP opposes the
activity of Axin. To gain further insight into the relation-
ship between Axin and GSK-3, we investigated the mech-
anism of action of the dominant-negative 
 
Xenopus
 
 GSK-3
(dnXgsk-3). Finally, we sought to clarify the role of APC 
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in 
 
Xenopus
 
 axis formation by determining the effects of
overexpressed APC on 
 
b
 
-catenin levels in the embryo.
We show here, both in vivo and in vitro, that GSK-3
cannot bind GBP and Axin simultaneously, leading to the
model that GBP functions in part to prevent GSK-3 bind-
ing to the Axin/APC/
 
b
 
-catenin complex. We show that
dnXgsk-3 binds Axin in vivo, and propose that it functions
to induce an ectopic axis in a manner analogous to GBP by
keeping endogenous 
 
Xenopus
 
 GSK-3 (Xgsk-3) from bind-
ing to
 
 
 
Axin. Additionally, we demonstrate that GBP in-
hibits Xgsk-3–mediated phosphorylation of protein sub-
strates without eliminating the kinase activity of Xgsk-3.
Finally, we show that the APC constructs that duplicate
the axis in 
 
Xenopus
 
 also stabilize 
 
b
 
-catenin, providing an
explanation for this surprising result. These results provide
a framework for understanding how positive and negative
regulators affect GSK-3 activity and, subsequently, 
 
b
 
-cate-
nin levels.
 
Materials and Methods
 
RNA Expression Constructs
 
The FLAG-epitope–tagged GBP mutant that does not bind Xgsk-3
(BP139), myc-epitope–tagged Xgsk-3 (XG134), and FLAG-epitope–
tagged wild-type GBP (BP20) have been described previously (Yost et al.,
1998). Axin-myc (Zeng et al., 1997), 
 
b
 
-catenin-myc (XBC40; Yost et al.,
1996), and XAPCFL, XAPC1, and XAPC4 (Vleminckx et al., 1997) also
have been described. Xgsk-3-FLAG (XG140) was constructed by cloning
the Xgsk-3 fragment from XG134 into CS2 
 
1 
 
FLAG. GBP-myc (BP25)
was constructed by cloning the GBP fragment from BP20 into CS2 
 
1 
 
MT
(Turner and Weintraub, 1994), and GBP-HA was constructed by cloning
this fragment into CS2 
 
1 
 
HA, a derivative of CS2
 
1
 
 (Turner and Wein-
traub, 1994) containing an HA epitope (details available upon request).
BP139-HA was constructed by cloning the mutant GBP from BP139 into
CS2 
 
1 
 
HA, and an HA-epitope–tagged 
 
b
 
-catenin was constructed by sub-
cloning 
 
b
 
-catenin from XBC40 into CS2 
 
1 
 
HA to generate XBC-HA. A
FLAG-epitope–tagged dominant-negative Xgsk-3 (XG210) was con-
structed as follows: the Xgsk-3–containing BamHI fragment from XG21
(Pierce and Kimelman, 1995) was cloned into CS2
 
1
 
 to make XG114. The
HindIII-EcoRV fragment of XG140 was replaced with the same fragment
from XG114 to generate XG210.
 
Embryos and Microinjection
 
Embryos were obtained as previously described (Newport and Kirschner,
1982). UV ventralization of embryos was performed as described (Ger-
hart et al., 1989). Embryos were microinjected (Moon and Christian,
1989) with RNA synthesized from CS2
 
1
 
 (Turner and Weintraub, 1994)
-derived constructs linearized with NotI or Asp718 using the mMessage
mMachine kit (Ambion) according to the manufacturer’s instructions.
 
Production of Proteins
 
rAxin (298-506) (Ikeda et al., 1998) was produced as an MBP fusion in
 
Escherichia coli
 
 (MBP-Axin). Recombinant MBP and MBP-Axin proteins
were purified over amylose resin (New England Biolabs) and eluted with
maltose according to the manufacturer’s directions. GSK-3 was produced
as a glutathione-S-transferase fusion in 
 
E
 
.
 
 coli
 
 (GST-GSK-3) (Ikeda et al.,
1998), purified over glutathione resin (Pharmacia Biotech), and eluted
with 20 mM glutathione. Kinase activity was confirmed using the peptide
phosphorylation assay as described (Wang et al., 1994). 
 
35
 
S-labeled pro-
teins were produced in Promega TNT coupled reticulocyte lysate systems
according to the manufacturer’s directions.
 
Immunoprecipitation, Western Blotting, and
Pull-down Assays
 
Immunoprecipitations and Western blotting were performed as described
(Yost et al., 1998), except for experiments involving detection of endoge-
nous APC. In this case, embryo lysates, prepared as described (Yost et al.,
1998), were electrophoresed on 4–12% gradient gels (Novex) and trans-
ferred to PVDF in Tris-glycine buffer lacking SDS and methanol. Endoge-
nous APC was immunoprecipitated and detected with anti-APC2 anti-
body (Rubinfeld et al., 1993; provided by P. Polakis). Anti-MBP antibody
was purchased from New England Biolabs, anti-GST antibody was pur-
chased from Amersham Pharmacia Biotech, and anti-HA antibody was
purchased from Santa Cruz Biotechnology. Extinction coefficients for
MBP, MBP-Axin, and GST-GSK-3 were calculated using ExPASy Prot-
Param and protein concentrations were determined by UV absorbance at
280 nm. 4 
 
m
 
g of GST-GSK-3 was incubated at room temperature with the
specified molar excess concentrations of MBP and MBP-Axin for 10 min
with 15 
 
m
 
g RNaseH in binding buffer (20 mM Tris, pH 7.4, 200 mM NaCl).
After this short incubation, 15 
 
m
 
g BSA and 9 
 
m
 
l of the [
 
35
 
S]GBP transla-
tion mix were added and the volume was increased to 1,500 
 
m
 
l with bind-
ing buffer. Proteins were nutated at 4
 
8
 
C for 1 h. 50 
 
m
 
l of prerinsed glu-
tathione resin was added to each reaction and proteins were nutated an
additional hour at 4
 
8
 
C. The resin was spun down for 1 min at 1,000 rpm
and washed four times in 1 ml PBS, 0.5% NP-40. Sample buffer was added
directly to the beads, and proteins were run on a 15% polyacrylamide gel.
Alternatively, 4 
 
m
 
g of MBP or MBP-Axin was incubated with 10 
 
m
 
g BSA
and 7 
 
m
 
l of the [
 
35
 
S]GBP 
 
6 
 
[
 
35
 
S]GSK-3 translation mix, in a final volume
of 1 ml binding buffer. Proteins were collected with 50 
 
m
 
l of prerinsed
amylose resin.
 
CREB Peptide Kinase Assay
 
Immunoprecipitates were washed as usual in NP-40 lysis buffer and were
washed additionally with 50 mM Tris, pH 8.0, plus 1 M NaCl, and finally in
50 mM Tris, pH 8.0. Kinase reactions were carried out essentially as de-
scribed (Wang et al., 1994) in a 30-
 
m
 
l reaction volume for 20 min at 30
 
8
 
C.
Levels of Xgsk-3-myc immunoprecipitated alone or with GBP were quan-
tified using densitometry and phosphorus-32 incorporation was normal-
ized to Xgsk-3 protein levels. CREB peptide and the prephosphorylated
p-CREB peptide were synthesized by Genosys.
 
Results
 
GSK-3 Cannot Bind GBP and Axin Simultaneously
 
The observations that Axin binds GSK-3 and 
 
b
 
-catenin
to promote the phosphorylation of 
 
b
 
-catenin by GSK-3
(Hart et al., 1998; Ikeda et al., 1998; Yamamoto et al.,
1998), and that GBP binds and inhibits GSK-3 (Yost et al.,
1998), led us to ask if GBP might function by preventing
GSK-3 from binding Axin. Coimmunoprecipitations and
in vitro pull-down assays were performed to address this
question. In the first set of experiments, we asked if the
presence of an excess of GBP could reduce the amount of
Axin coimmunoprecipitated with Xgsk-3, when the levels
of the latter two were kept constant. RNA constructs
encoding FLAG-epitope–tagged Xgsk-3 (
 
Xgsk-3-FLAG
 
)
and myc-epitope–tagged GBP (
 
GBP-myc
 
) and Axin
(
 
Axin-myc
 
) (Zeng et al., 1997) were injected into the ani-
mal region of two- to eight-cell stage 
 
Xenopus
 
 embryos.
Embryos were lysed after 4–5 h, and immunocomplexes
were precipitated with anti-FLAG antibodies. The immu-
noprecipitates were analyzed on a blot with both anti-
FLAG and anti-myc antibodies. In preliminary experi-
ments, injection of a combination of 50 pg of 
 
Xgsk-3
 
 RNA
and 1 ng of 
 
Axin
 
 RNA was shown to result in the produc-
tion of an excess of Axin protein relative to Xgsk-3 (data
not shown). Coinjection of increasing amounts of 
 
GBP
 
RNA with this mixture of 
 
Xgsk-3
 
 and 
 
Axin
 
 RNAs resulted
in a decrease of Axin coimmunoprecipitated with Xgsk-3
(Fig. 1 a, lanes 2–6), though both were produced at the
same level in all samples. To demonstrate that the reduc-
tion in the amount of Axin bound to Xgsk-3 is specifically 
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dependent on GBP binding to Xgsk-3, the coimmunopre-
cipitation experiment was repeated using a high dose of
HA-tagged GBP (GBPwt) or an equivalent amount of the
HA-tagged GBP mutant that does not bind Xgsk-3 (Yost
et al., 1998) (GBPmut). The level of Axin coimmunopre-
cipitated by Xgsk-3 was reduced by expression of GBPwt
but not by GBPmut (Fig. 1 b). These results indicate that
GBP can prevent the association of Axin and Xgsk-3, ei-
ther by displacing Axin from Xgsk-3, or by preventing the
formation of Axin–Xgsk-3 complexes.
In a complementary set of experiments, we asked if
GBP could join a GSK-3–Axin complex. For these experi-
ments, the GSK-3 binding region of rat Axin, rAxin (298-
506), which binds GSK-3 as well as full-length Axin
(Ikeda et al., 1998), was purified as a maltose binding pro-
tein fusion (MBP-Axin) and GSK-3 was purified as a glu-
tathione-S-transferase fusion (GST-GSK-3
 
b
 
) (Ikeda et al.,
1998). GBP was synthesized, sulfur-35–labeled in vitro,
and was added to mixtures of GST-GSK-3
 
b
 
 and increasing
amounts of MBP-Axin or MBP. After an incubation,
GST-GSK-3
 
b
 
 was collected on glutathione-conjugated
Sepharose beads, and the levels of [
 
35
 
S]GBP associated
 
with GST-GSK-3
 
b 
 
were determined by SDS-PAGE and
autoradiography. Whereas [
 
35
 
S]GBP did not significantly
bind the glutathione resin (Fig. 2 a, lane 2) or GST (data
not shown), it effectively bound GST-GSK-3
 
b
 
 (Fig. 2 a,
lane 3). Inclusion of increasing amounts of MBP-Axin
with GST-GSK-3
 
b resulted in less [35S]GBP binding to
GST-GSK-3b (Fig. 2 a, lanes 4–7). At a 50-fold molar ex-
cess of MBP-Axin to GST-GSK-3b, binding of [35S]GBP
was completely eliminated compared with the background
(Fig. 2 a, compare lanes 6 and 2). This effect is specifically
dependent on MBP-Axin binding to GST-GSK-3b since
substituting even a 1,000-fold molar excess of maltose
binding protein (MBP) does not significantly affect [35S]GBP
binding (Fig. 2 a, lane 11).
While these results were consistent with the hypothesis
that GSK-3 can be bound to either GBP or Axin, it was
also possible that MBP-Axin binds GBP and this interac-
tion prevents GBP from interacting with GSK-3. To test
this, we examined the ability of MBP-Axin to pull down
[35S]GBP. As shown in Fig. 2 b, whereas MBP-Axin effec-
Figure 1. (a) GBP blocks GSK-3 binding to Axin in vivo. Em-
bryos were injected at the two to eight-cell stage in the animal
pole with 50 pg Xgsk-3-FLAG and 1 ng Axin-myc along with in-
creasing doses of GBP-myc, as indicated. After 4–5 h, proteins
were isolated by immunoprecipitation with anti-FLAG antibody
and detected by Western blotting (left panel). An aliquot of each
sample taken before immunoprecipitation is shown in the right
panel (Total Lysates); the level of Xgsk-3 produced is not detect-
able in these samples (z1 embryo). A portion of the total lysate
shown in lane 6 was precipitated in the absence of anti-FLAG an-
tibody as a negative control (lane 7). Lane numbers in the right
panel refer to the same injections as shown above the cor-
responding lane numbers in the left panel. (b) Prevention of
GSK-3–Axin binding by GBP is dependent on GBP/GSK-3 bind-
ing. Embryos were injected with Axin-myc and Xgsk-3-FLAG as
above along with 4 ng HA-tagged wild-type (GBPwt) or the
HA-tagged point mutant that does not bind GSK-3 (GBPmut).
Immunoprecipitations were performed as above. No GBP is
present in the anti-FLAG immunoprecipitates in lane 4 since this
is the GSK-3 binding mutant of GBP. Lane numbers in the right
panel refer to the same injections as shown above the corre-
sponding lane numbers in the left panel.
Figure 2. (a) GBP and Axin do not bind GSK-3 at the same time.
Bacterially produced GST-GSK-3b and MBP-Axin or MBP were
incubated with [35S]methionine-labeled GBP. MBP-Axin or
MBP was present in excess over GST-GSK-3b as indicated. Pro-
tein complexes were precipitated with glutathione-Sepharose
beads and [35S]GBP was detected by SDS-PAGE and autora-
diography. MBP-Axin/MBP levels were detected by SDS-PAGE
and anti-MBP Western blotting of 0.33% input. IVT, an aliquot
of the in vitro translation reaction; 11% of binding reaction input.
Neg. control,  [35S]GBP incubated with glutathione-Sepharose
beads. The level of GST-GSK-3 pulled down in each sample was
detected by anti-GST Western blotting. (b) GBP does not bind
MBP-Axin directly or through an interaction with GSK-3. Bacte-
rially produced MBP-Axin was incubated with [35S]methionine-
labeled in vitro translated GBP in the presence or absence of
[35S]methionine-labeled Xgsk-3. Protein complexes were precipi-
tated with amylose resin, and GBP and Xgsk-3 were detected by
SDS-PAGE and autoradiography. IVT, an aliquot of the in vitro
translation reaction; 14% of binding reaction input. MBP-Axin/
MBP levels were detected by SDS-PAGE and anti-MBP West-
ern blotting of 1% of the input. Farr et al. Interaction among Intracellular Wnt Factors 695
tively binds [35S]GSK-3 (lane 6), it does not interact with
[35S]GBP (Fig. 2 b, lane 4). Moreover, MBP-Axin does not
associate with [35S]GBP when [35S]GSK-3 is present (Fig. 2
b, lane 5), supporting the idea that the three proteins do
not form a ternary complex.
GBP Does Not Inhibit the Ability of Xgsk-3 to 
Phosphorylate a Peptide Substrate
The demonstration that GBP and Axin cannot bind GSK-3
simultaneously suggests that GBP might inhibit GSK-3
by removing it from the Axin complex or by preventing
GSK-3 from associating with Axin. Since we previously
demonstrated that GBP inhibits the in vivo phosphoryla-
tion of tau (Yost et al., 1998), a protein not thought to be
involved in Wnt signaling, we wanted to examine whether
GBP might also be able to inhibit GSK-3 by binding and
inactivating the catalytic site. We used a modification of
a published assay for GSK-3 activity that measures the
ability of GSK-3 to phosphorylate the peptide substrate
P-CREB, which contains a GSK-3 consensus phosphoryla-
tion site, in comparison to the negative control peptide,
CREB (Wang et al., 1994). Embryos were injected with
RNA encoding Xgsk-3-myc together with control RNA
or GBP-FLAG (Yost et al., 1998) RNA and, after 3 h,
proteins were extracted and immunoprecipitated. Anti-
FLAG antibodies were used to isolate Xgsk-3 bound to
GBP when both were injected; anti-myc antibodies were
used to isolate Xgsk-3 when it was injected with a control
RNA; and uninjected embryos were immunoprecipitated
with both antibodies to measure background. The im-
munoprecipitates were incubated with g-[32P]ATP in ki-
nase buffer containing P-CREB or CREB, and the incor-
porated radioactivity was quantified. Western blotting
showed that GBP and Xgsk-3 were both expressed and ef-
ficiently immunoprecipitated, and remained associated
throughout the assay (data not shown). As shown in Fig. 3,
GBP does not affect the ability of Xgsk-3 to phosphorylate
this peptide substrate. This shows that GBP can inhibit
GSK-3 in a way that does not inactivate its catalytic activity.
The Dominant-negative Xgsk-3 Binds Axin
It has been shown in a number of studies, including our
own, that mutation of a conserved lysine in the ATP bind-
ing region of GSK-3 results in a kinase-deficient mutant
that acts as a dominant-negative mutant (dnXgsk-3) in Xe-
nopus (Dominguez et al., 1995; He et al., 1995; Pierce and
Kimelman, 1995). The demonstration that Axin binds
GSK-3 and promotes the phosphorylation of b-catenin
suggests that the dnXgsk-3 might function by binding Axin
and keeping it from binding endogenous Xgsk-3. How-
ever, studies in a mammalian system have shown that ki-
nase dead GSK-3 does not bind Axin (Ikeda et al., 1998),
indicating that the kinase dead dnXgsk-3 might stabilize
b-catenin by an alternative mechanism. To investigate this
issue, we compared Xgsk-3 and dnXgsk-3 binding to Axin
in coimmunoprecipitation experiments. Axin-myc was
coinjected with either Xgsk-3-FLAG or dnXgsk-3-FLAG
in Xenopus embryos, and expressed proteins were immu-
noprecipitated with anti-FLAG antibodies. Immunocom-
plexes were analyzed by Western blotting with anti-myc
and anti-FLAG antibodies. As expected, Axin is immuno-
precipitated by Xgsk-3 (Fig. 4, lane 7). In addition, Axin is
immunoprecipitated equally well by dnXgsk-3 (Fig. 4, lane
8). Thus, unlike in the mammalian system, the kinase dead
mutant of Xgsk-3 binds Axin, suggesting that it stabilizes
b-catenin either by displacing endogenous Xgsk-3 from
the Axin complex, or by preventing association of Axin
and endogenous Xgsk-3.
Truncated APC Stabilizes b-Catenin
Various lines of evidence have implicated APC in the
downregulation of b-catenin. In the colon cancer cell line
SW480, for example, a mutation that truncates APC in the
Figure 3. GBP does not inhibit Xgsk-3 phosphorylation of a pep-
tide substrate. Embryos were injected with RNA encoding Xgsk-
3-myc together with control RNA or GBP-FLAG RNA. After 3 h,
proteins were extracted and immunoprecipitated with anti-
FLAG (Xgsk-3 1 GBP), anti-myc (Xgsk-3 1 control), or both
(uninjected) antibodies. The kinase activity of immune com-
plexes was measured by phosphorus-32 incorporation into the
GSK-3–specific substrate prephosphorylated CREB peptide
(p-CREB; dark bars). The nonphosphorylated CREB peptide
(CREB; light bars) is not a GSK-3 substrate and was used as a
control. The activity of duplicate immune complexes is shown.
Figure 4. Dominant-negative Xgsk-3 binds Axin. Embryos were
injected at the two- to eight-cell stage with 1 ng Axin-myc, 0.5 ng
Xgsk-3-FLAG, and 0.5 ng dnXgsk-3-FLAG in the animal pole.
Embryo extracts were precipitated with anti-FLAG antibody and
detected by Western blotting (left panel). An aliquot of each
sample taken before immunoprecipitation is shown in the right
panel (Total Lysates). Lane numbers in the right panel refer to
the same injections as shown above corresponding lane numbers
in the left panel.The Journal of Cell Biology, Volume 148, 2000 696
20–amino acid repeat region leads to the accumulation of
high levels of b-catenin (for review see Polakis, 1997).
When full-length APC, or deletion constructs containing
the central 20–amino acid repeat region, are introduced
into these cells, b-catenin levels are reduced (Munemitsu
et al., 1995). Given these results, APC would be predicted
to have a ventralizing activity in Xenopus. However, ec-
topic expression of APC, or the deletion mutants that
lower  b-catenin levels in cells, on the ventral side of Xeno-
pus embryos resulted in a duplicated dorsal axis and the
induction of a b-catenin–dependent gene, siamois (Vlem-
inckx et al., 1997). These effects would be expected if
b-catenin was stabilized by the ectopic APC, but no stabi-
lization was detected. Cytoplasmic b-catenin was required
for this effect, however, because coexpression of C-cad-
herin, which sequesters b-catenin to the plasma mem-
brane, abolished axis duplication by ectopic APC. There-
fore, it was proposed that in Xenopus, APC functions as a
positive regulator of dorsal axis formation in a manner not
requiring b-catenin stabilization, but dependent upon cy-
toplasmic b-catenin (Vleminckx et al., 1997).
Since we were interested in understanding this poten-
tially novel means of b-catenin regulation by APC, we re-
peated the ectopic expression experiments with APC. Like
Vleminckx et al. (1997), we observed that ectopic full-
length Xenopus APC (XAPCFL) has axis-inducing activ-
ity (Fig. 5 b). Whereas the previous study measured the
ability of XAPCFL to induce a dorsal axis when ectopi-
cally expressed on the ventral side of the embryo, we mea-
sured the ability of XAPCFL to induce an axis in embryos
whose endogenous axis has been ablated by UV light.
Whereas the latter assay (the UV rescue assay) is more
easily quantified than secondary axis formation, the two
assays measure the same process.
When we examined the expression of ectopic XAPCFL,
using the myc-epitope tag located at the NH2 terminus, we
noticed that the APC protein migrated as a series of forms
that were less than the expected molecular mass of 320 kD
(Fig. 5 c). While the exact pattern of these smaller molecu-
lar mass forms detected varied between experiments, the
truncated forms were always observed to be the major
products produced. Since the myc-epitope tag is located at
Figure 5. Regulation of b-catenin levels by Xenopus APC. (a) XAPC constructs used in axis rescue and b-catenin stabilization experi-
ments. (b) XAPC induces an axis in Xenopus. In two separate experiments, RNA encoding different forms of XAPC was injected at the
doses indicated into the marginal zone of UV-irradiated embryos and the degree of axis rescue was determined at tadpole stages. An
unaffected embryo has a DAI of 5 and a completely ventralized embryo has a DAI of 0. Uninjected ventralized UV control embryos
are indicated for each experiment. Bars indicate SD and numbers above bars indicate the number of embryos scored for each injection.
(c) Truncated forms of XAPCFL result from its overexpression in Xenopus embryos. RNA encoding myc-tagged versions of XAPC
were injected into cleavage stage embryos. After a 4-h incubation, embryo extracts were collected and immunoprecipitated with anti-
myc antibody. After SDS-PAGE, protein products were detected by Western blot with anti-myc antibodies. (d) The observed truncated
products are present in the intact embryo. Uninjected embryos and sibling embryos injected with 5.6 ng myc-tagged XAPCFL were im-
munoprecipitated with anti-APC2, anti-myc, or anti-HA (negative control) antibody as indicated. After SDS-PAGE, APC was de-
tected using anti-APC2 or anti-myc antibody, as indicated. Endogenous APC is not detected in the sample injected with XAPCFL
(lanes 3–6) because this sample was not immunoprecipitated with the APC2 antibody. The lower molecular mass forms of XAPCFL are
not observed with the anti-APC2 antibody which binds to the central region of APC.Farr et al. Interaction among Intracellular Wnt Factors 697
the NH2 terminus of the APC constructs, the smaller
forms we observe are due to COOH-terminal truncations.
XAPC1 and XAPC4, which also induce an ectopic axis
(Fig. 5 b and Vleminckx et al., 1997), migrated at their ex-
pected molecular mass (Fig. 5 c).
We next wished to determine if the observed truncated
protein products we observed when we injected XAPCFL
might be generated during processing of the embryos for
immunoprecipitation or if they were present in the intact
cells. Lysate from uninjected embryos was immunoprecip-
itated with antibody to APC (Rubinfeld et al., 1993) in
parallel with lysate from embryos injected with XAPCFL,
which was immunoprecipitated with antibody to the myc
epitope. A single band of endogenous APC was detected
in the uninjected sample (Fig. 5 d, lane 1), whereas in-
jected siblings produced a variety of faster migrating spe-
cies in addition to full-length myc-tagged APC (Fig. 5 d,
lane 3). Blotting the XAPCFL-injected sample with the
anti-APC2 antibody shows that this antibody is capable of
recognizing the larger of the truncated products (Fig. 5 d,
lane 5). Because this antibody was generated against only
the central third of APC, it would not be expected to rec-
ognize truncations that contain only the NH2-terminal
third or less of APC. Because endogenous APC appeared
undegraded, the lysis and immunoprecipitation protocols
are not responsible for the observed truncated XAPCFL
products. Importantly, this indicates that these truncated
products are actually present in the embryo before lysis.
Next, we wished to reexamine the results obtained by
Vleminckx et al. (1997) in a b-catenin stabilization exper-
iment, in which an assay we developed (Yost et al., 1996)
was used to claim that b-catenin levels were unchanged
by injection of full-length XAPC RNA into Xenopus em-
bryos. Low levels of ectopically expressed myc-tagged
b-catenin are used to measure the rate of b-catenin degra-
dation in this assay, which is very sensitive to the dose of
injected b-catenin-myc (Yost et al., 1996). At the dose of
b-catenin-myc used by Vleminckx et al. (1997) (1 ng), we
were concerned that it was not possible to measure the
degradation of the ectopically expressed b-catenin since it
overwhelms the endogenous degradation machinery. To
test this, embryos were injected with a range of doses of
b-catenin-myc from 10 pg to 500 pg, with or without 1 ng
of GBP-myc to stabilize b-catenin levels, and with a con-
trol RNA (GFP) to equalize the mass of RNA injected
for each treatment (Fig. 6 a). When 50 pg or less of b-cate-
nin-myc was used, there was an increase in the levels of
b-catenin protein when GBP-myc was coinjected with
b-catenin-myc. Above this dose, however, b-catenin lev-
els were identical in the presence and absence of GBP.
Therefore, the previous measurement of b-catenin stabil-
ity by Vleminckx et al. (1997) would not have given a mean-
ingful result. To reexamine whether ectopic XAPCFL
stabilizes b-catenin, embryos were injected with two
doses of XAPCFL RNA along with 50 pg b-catenin-myc
RNA. The high dose of XAPCFL caused significant axis
rescue in UV-irradiated embryos, whereas the low dose
did not (not shown). Correspondingly, the high dose of
XAPCFL stabilized b-catenin, whereas the low dose did
not (Fig. 6 b).
Because the major product produced from injection of
XAPCFL RNA was similar in size to the NH2-terminal
fragment XAPC1 (Fig. 5 c), and because XAPC4 contains
the b-catenin binding domain, we next asked if these two
constructs could rescue the axis and stabilize b-catenin.
Both XAPC1 and XAPC4 caused significant axis rescue in
UV-irradiated embryos (Fig. 5 b). The b-catenin stabiliza-
tion experiment was performed using a dose of RNA that
was at least as high as that required to give good axis res-
cue. In this experiment, b-catenin tagged with an HA
epitope was used so that the myc-epitope–tagged XAPC
constructs would not interfere with the detection of the ec-
topic b-catenin. Both XAPC1 and XAPC4 were found to
enhance the levels of b-catenin (Fig. 6 c). Because axis
rescue and b-catenin stabilization were observed with the
deletion constructs, and because a variety of truncated
products accumulate in the intact embryo when XAPCFL
is overexpressed, it is likely that the effects seen with
XAPCFL are due to the production of truncated products.
Figure 6. Truncated APC products cause axis duplication
through  b-catenin stabilization. Detection of b-catenin-myc sta-
bilization depends upon the dose of RNA injected. Embryos
were injected at the two- to eight-cell stage in the animal pole
with the indicated dose of b-catenin-myc, with or without 1 ng
GBP-myc as indicated, and with a control RNA (GFP) to yield a
total of 2 ng of injected RNA per treatment. Embryos were lysed
at stage 8 and approximately one embryo equivalent from each
treatment was analyzed by Western blotting with the anti-myc
antibody. (b) Ectopic XAPC stabilizes b-catenin. Embryos were
injected with 50 pg of RNA encoding myc-tagged b-catenin alone
or together with XAPCFL RNA (0.15 or 1.5 ng). Control em-
bryos were uninjected. After 4 h, protein samples were collected
for Western analysis and b-catenin-myc was detected with anti-
myc antibody. In parallel experiments, the ability of these RNAs
to induce an axis in UV irradiated embryos was measured. (c)
XAPC1 and XAPC4 stabilize b-catenin. Embryos were injected
with 50 pg of RNA encoding HA-tagged b-catenin together with
2 ng GBP (positive control), GFP (negative control), XAPC1, or
XAPC4 RNA. After 4 h, protein samples were collected for
Western analysis and b-catenin-HA was detected with anti-HA
antibody.The Journal of Cell Biology, Volume 148, 2000 698
Discussion
While the most upstream components of the Wnt signaling
pathway, Wnt and Dishevelled, are sufficient to induce an
ectopic axis when overexpressed in Xenopus (McMahon
and Moon, 1989; Smith and Harland, 1991; Sokol et al.,
1991; Rothbacher et al., 1995; Sokol et al., 1995), neither
has been shown to be required for formation of the endog-
enous axis. This suggests the interesting possibility that the
downstream components of the pathway, including the
serine/threonine kinase GSK-3, are regulated in a unique
way in the early embryo, independent of Wnt ligand. The
regulation of GSK-3 has been shown to be critical for
proper dorsal–ventral axis specification in Xenopus (Do-
minguez et al., 1995; He et al., 1995; Pierce and Kimel-
man, 1995). GSK-3 functions as part of a multiprotein
complex in which Axin directly binds GSK-3, b-catenin,
and APC (Hart et al., 1998; Ikeda et al., 1998; Itoh et al.,
1998; Nakamura et al., 1998; Sakanaka et al., 1998; Yama-
moto et al., 1998), and promotes the phosphorylation of
b-catenin by GSK-3 (Hart et al., 1998; Ikeda et al., 1998;
Yamamoto et al., 1998). We previously demonstrated that
GBP inhibits the Xgsk-3–mediated phosphorylation of an
in vivo protein substrate, tau, in a manner dependent on
GBP binding to Xgsk-3 (Yost et al., 1998). Therefore,
Axin and GBP both bind to GSK-3, but have opposite ef-
fects on its activity. Based on the data implicating Axin in
the positive regulation of GSK-3, we hypothesized that
GBP might function to prevent GSK-3 from binding Axin.
Using both in vivo and in vitro approaches, we show here
that GBP and Axin do not simultaneously bind to GSK-3.
In embryos, when a limiting amount of Xgsk-3 was coex-
pressed with an excess of Axin, addition of GBP reduced
the amount of Xgsk-3 bound to Axin. In vitro, when GBP
was limiting, increasing amounts of Axin prevented GBP
from binding to GSK-3. Axin did not bind GBP in vitro,
either directly or in the presence of GSK-3. Moreover,
when Axin, Xgsk-3, and GBP were coexpressed in em-
bryos at comparable levels, immunoprecipitation of GBP
brought down Xgsk-3 but not Axin, demonstrating that
these proteins cannot form a trimolecular complex (data
not shown). Importantly, it also has been observed re-
cently in mammalian cells that the GBP homologue,
FRAT1, reduces the amount of Axin that can be coimmu-
noprecipitated with GSK-3 (Yuan et al., 1999), demon-
strating that this mechanism of GSK-3 regulation is con-
served among vertebrates. Taken together, the in vivo and
in vitro data support a model in which GSK-3 activity can
be controlled by its preferential binding to either GBP or
Axin.
GBP Does Not Inhibit GSK-3 Kinase Activity
Since the inhibition of tau phosphorylation requires GBP
binding to Xgsk-3 (Yost et al., 1998), we hypothesized that
GBP could bind to GSK-3 in a manner that inactivates its
catalytic cleft. This mechanism has been shown for the in-
teraction between Cdk2, which shares a high degree of se-
quence homology with GSK-3, and the Kip/Cip family of
CDK inhibitors, which includes p21Cip1,WAF-1, p27Kip1, and
p57Kip2. When p27Kip1 binds to Cdk2, it causes large struc-
tural changes in the NH2 terminus and catalytic cleft,
which eliminates ATP binding and kinase activity (Russo
et al., 1996). Using a peptide phosphorylation assay, we
find that Xgsk-3 kinase activity is not inhibited by GBP
binding. Additionally, FRAT1 does not affect the ability
of GSK-3 to phosphorylate a peptide substrate (Yuan et al.,
1999). Taken together, the results from the tau assay and
the peptide assay suggest that GBP binds to GSK-3 in a
manner that does not inhibit the catalytic activity of the
active site, unlike the case for p27Kip1 binding to Cdk2.
GBP might sterically block access of protein substrates to
the active site of GSK-3, and we are currently attempting
to map the residues of Xgsk-3 that are important for GBP
binding to Xgsk-3 to determine if GBP might bind in the
region of Xgsk-3’s active site. These results also show that
this widely used assay of GSK-3 activity in some important
cases may not accurately reflect the extent of GSK-3 func-
tional inhibition.
The Dominant-negative Xgsk-3 Binds Axin
Mutation of a lysine residue, conserved in all kinases, in
the ATP binding domain of GSK-3 creates a kinase-defi-
cient protein that acts as a dominant-negative mutant in
Xenopus. Overexpression of this mutant on the ventral
side of embryos results in the formation of a second body
axis (Dominguez et al., 1995; He et al., 1995; Pierce and
Kimelman, 1995) by locally preventing the degradation of
b-catenin (Yost et al., 1996; Larabell et al., 1997). It was
previously assumed that dnXgsk-3 functions by competing
with endogenous Xgsk-3 for substrates or regulatory mol-
ecules. The demonstration that Axin binds GSK-3 and
b-catenin and promotes GSK-3 phosphorylation of b-cat-
enin suggested that Axin might be the target of the
dnXgsk-3. However, Ikeda et al. (1998) showed that a ki-
nase-deficient mammalian GSK-3 analogous to ours does
not bind Axin in cell culture, and other workers have
found that similar GSK-3 mutants do not act as domi-
nant-negatives in the Wnt pathway in mammalian cells
(Woodgett, J., personal communication). A different
GSK-3 kinase mutant, GSK-3Y.F also coimmunopre-
cipitates less Axin than wild-type GSK-3 in mammalian
cells (Yuan et al., 1999). Furthermore, Akt, which inhib-
its GSK-3 by phosphorylating it, reduces the amount
of Axin coimmunoprecipitated by GSK-3 (Yuan et al.,
1999). However, we show here that the dominant-nega-
tive Xgsk-3 and wild-type Xgsk-3 bind Axin equally well
in vivo. This is consistent with a model in which over-
expressed kinase-deficient Xgsk-3 acts as a dominant-
negative either by displacing endogenous Xgsk-3 already
bound to Axin or by preventing endogenous Xgsk-3 from
binding Axin as new complexes form. In either case, en-
dogenous Xgsk-3 is prevented from phosphorylating
b-catenin by the dominant-negative Xgsk-3 because it is
prevented from associating with Axin. In mammalian
cells, the lack of a dominant-negative activity for kinase-
deficient GSK-3 can be attributed to its inability to bind
Axin. It is unclear why a more severe mutation in a mam-
malian GSK-3 than that of Ikeda et al. (1998) apparently
retains its ability to bind Axin in vitro (Sakanaka et al.,
1998). However, it was not addressed whether this mu-
tant acted as a dominant-negative.Farr et al. Interaction among Intracellular Wnt Factors 699
Overexpressed APC Induces Axis Formation by 
Stabilizing b-Catenin
APC appears to be an important regulator of b-catenin
levels and, as such, has been implicated in cancer progres-
sion and in development (for reviews see Polakis, 1997;
Bienz, 1999). Evidence from tissue culture suggests that
APC functions in conjunction with GSK-3 and Axin to
downregulate b-catenin levels, and that GSK-3 phosphor-
ylates both APC and b-catenin as a prerequisite for
b-catenin degradation (Rubinfeld et al., 1996). Data ob-
tained from a study overexpressing APC in Xenopus,
however, suggested that the role of APC in frog embryos
might be different. Vleminckx et al. (1997) showed that
APC could induce an ectopic axis and induce expression
of siamois, apparently without stabilizing b-catenin, though
cytoplasmic  b-catenin was required. The authors con-
cluded that Xenopus APC has a signaling role indepen-
dent of b-catenin regulation.
Studies in C. elegans have shown that Wnt signaling is
also involved in establishing cell polarity in the EMS cell
division (Rocheleau et al., 1997; Thorpe et al., 1997).
Downstream components of the Wnt pathway, however,
including POP-1 (TCF), WRM-1 (b-catenin), and APR-1
(APC), may be used differently in worms than in other or-
ganisms (for review see Han, 1997). For example, WRM-1
is required for excluding POP-1 from the nucleus of the E
cell, allowing that cell to develop as an endoderm (Lin et
al., 1998). In vertebrates, in contrast, b-catenin interacts
with Tcf-1 in the nucleus to activate transcription. Further-
more, RNAi loss-of-function experiments have shown that
apr-1(RNAi) and wrm-1(RNAi) C. elegans embryos have
similar defects in E blastoderm development, suggesting
that APR-1 positively regulates WRM-1 (Rocheleau et al.,
1997).
Our results support a model in which APC acts to down-
regulate b-catenin in Xenopus. We found that injection of
RNA encoding full-length APC (XAPCFL) in Xenopus
results in the accumulation of a number of COOH termi-
nally truncated products, presumably because of either in-
complete translation or proteolytic cleavage in the em-
bryo. While we (Fig. 5 d) and Vleminckx et al. (1997) did
detect a high molecular mass APC product from injected
RNA, both studies also observed the presence of trun-
cated species. We also found that a level of XAPCFL,
XAPC1, or XAPC4 RNA that rescues axis formation in
UV-irradiated embryos also stabilizes b-catenin levels.
Thus, we conclude that the APC products expressed from
the injected RNA induce an ectopic axis by increasing
b-catenin levels, as is observed when Wnt (Larabell et al.,
1997), b-catenin (Funayama et al., 1995; Yost et al., 1996),
dnXgsk-3 (Yost et al., 1996), or GBP (Yost et al., 1998) are
overexpressed in Xenopus embryos. No alternate or paral-
lel pathway needs be invoked to explain the axis-inducing
effect of ectopically expressed APC in Xenopus.
Because the various deletion constructs cause axis for-
mation through b-catenin stabilization, we propose that
the effects of ectopic XAPCFL are mediated not by the
full-length protein, but by the abundant truncated prod-
ucts. We suggest that the ability of ectopic APC to induce
an axis in Xenopus is a dominant-negative effect in which
the truncated APC products displace the endogenous
APC from its normal partners. XAPC4, for example, con-
tains two of the three Axin binding domains identified in
APC (Behrens et al., 1998; Hart et al., 1998), and is likely
to displace endogenous APC from the Axin–Xgsk-3 com-
plex, preventing it from participating in the degradation
of b-catenin. Supporting this interpretation, it has been
shown that an APC fragment that binds Conductin sta-
bilizes b-catenin in Neuro2A cells and prevents APC-
induced degradation of b-catenin in SW480 cells (Beh-
rens et al., 1998). However, a fragment of human APC
similar to XAPC4 reduces cytoplasmic b-catenin levels in
SW480 cells (Munemitsu et al., 1995). The different effects
of this central part of APC on b-catenin stability may be
accounted for by differences in the systems examined. For
example, a dominant-negative effect may depend on full-
length APC, present in Xenopus but not in SW480 cells, or
that more protein may be produced by overexpression in
Xenopus than transfection of mammalian cells. Unlike
Vleminckx et al. (1997), we also observed axis rescue by
XAPC1, which is the most NH2-terminal fragment and
lacks the identified Axin binding domains (Fig. 5 a). This
fragment contains an NH2-terminal oligomerization do-
main (Su et al., 1993), which could bind the endogenous
APC and block its function, and also a domain of Arm re-
peats, which might be expected to mediate an interaction
between APC and an unidentified partner.
Figure 7. Model for GSK-3 regulation in the
early Xenopus embryo. (a) On the ventral side
of the embryo, GSK-3 is part of a functional
degradation complex that includes APC and
Axin. When in this complex, GSK-3 phosphory-
lates b-catenin, targeting it for degradation via
the proteosome pathway. Under these condi-
tions, dorsal genes are repressed. (b) On the
dorsal side of the embryo, GSK-3 is excluded
from the Axin–APC complex by GBP. In addi-
tion, GBP may prevent GSK-3 from phosphory-
lating its normal substrates by blocking access
to the active site. b-Catenin accumulates and
activates the transcription of dorsal genes.
(c) The kinase-deficient dnXgsk-3 functions
by binding Axin, thus, keeping endogenous Xgsk-3 from the degradation complex. As in the situation with GBP, b-catenin accumu-
lates and activates the transcription of dorsal genes.The Journal of Cell Biology, Volume 148, 2000 700
Model for GSK-3 Dorsal–Ventral Regulation
in Xenopus
The coordinated regulation of GSK-3 activity by both pos-
itive and negative regulators is critical for a wide range of
downstream effects, from insulin regulation to develop-
mental processes (for review see Yost et al., 1997). The ex-
periments presented here advance our understanding of
GSK-3 regulation and allow us to propose the following
model for Xgsk-3 regulation in the fertilized Xenopus egg.
On the ventral side, b-catenin levels are kept low by Xgsk-
3–dependent phosphorylation in a complex including Axin
and APC (Fig. 7 a). Phosphorylation of Axin and APC by
Xgsk-3 may be required to assemble this complex. On the
dorsal side, GBP inhibits phosphorylation of b-catenin ei-
ther by displacing Xgsk-3 from the Axin/APC/Xgsk-3
complex or by prebinding GSK-3 and preventing its asso-
ciation with the Axin–APC complex. GBP binding to
Xgsk-3 may block access of protein substrates to the active
site (Fig. 7 b). GBP might also prevent Xgsk-3 from phos-
phorylating Axin and APC, and thereby further inhibit
complex formation. The dominant-negative Xgsk-3 acts in
a manner analogous to GBP since it either displaces wild-
type Xgsk-3 from the complex, or binds endogenous Xgsk-3
and prevents its binding to Axin, thus, inhibiting b-catenin
degradation (Fig. 7 c).
The complete chain of molecular events linking fertiliza-
tion and the dorsal enrichment of b-catenin has yet to be
determined, but this study brings us closer to understand-
ing the interactions of key players. It will ultimately be
very interesting to elucidate the relative dorso-ventral
abundance of each of these proteins in the Xenopus oo-
cyte and fertilized embryo. However, it may not be just the
relative abundance of each of these players that specifies
the endogenous axis. Alternatively, posttranslational mod-
ifications and/or the presence of yet unidentified factors
could affect dorso-ventral differences in known players.
GBP is a candidate for the dorsal determinant, and we are
developing the reagents to examine the possible dorsal lo-
calization or dorsal modification of GBP. Alternatively,
GBP may be ubiquitous, but be activated or recruited to
function by another factor that becomes dorsally localized
in response to sperm entry. The determinant might, for ex-
ample, bind to the Axin/APC/Xgsk-3 complex and alter its
conformation in such a way as to allow GBP to bind Xgsk-3
and remove it from the complex. In this regard, the obser-
vation that Dishevelled interacts with GBP (Li et al., 1999)
and Axin (Kishida et al., 1999; Smalley et al., 1999) and is
dorsally enriched in the early Xenopus embryo (Miller et
al., 1999) is very suggestive of such a mechanism. Alterna-
tively, GBP might function together with Dishevelled
to prevent the initial formation of complexes between
Axin and GSK-3 in the dorsal cortical cytoplasm, rather
than functioning to disrupt complexes once they have
formed.
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Note Added in Proof. While this work was under review, a study was pub-
lished showing that a peptide derived from the GSK-3 binding region of
FRAT1 prevents the association of Axin and GSK-3 in agreement with
the results presented here (Thomas, G.M., S. Frame, M. Goedert, L.
Nathke, P. Polakis, and P. Cohen. 1999. FEBS (Fed. Eur. Biochem. Soc.)
Lett. 458:247–251.
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